Literature DB >> 12023542

Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats.

Eugen Davids1, Kehong Zhang, Nora S Kula, Frank I Tarazi, Ross J Baldessarini.   

Abstract

Consistent with their clinical effects in attention deficit-hyperactivity disorder (ADHD), the stimulants methylphenidate and amphetamine reduce motor hyperactivity in juvenile male rats with neonatal 6-hydroxydopamine (6-OHDA) lesions of the forebrain dopamine (DA) system. Since stimulants act on several aminergic neurotransmission systems, we investigated underlying mechanisms involved by comparing behavioral actions of d-methylphenidate, selective inhibitors of the neuronal transport of DA [GBR-12909 (1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-[3-phenylpropyl]piperazine dihydrochloride), amfonelic acid], serotonin [5-hydroxytryptamine (5-HT), citalopram, fluvoxamine], and norepinephrine (NE; desipramine, nisoxetine) in 6-OHDA lesioned rats. Selective dopamine lesions were made using 6-OHDA (100 microg, intracisternal) on postnatal day (PD) 5 after desipramine pretreatment (25 mg/kg, s.c.) to protect noradrenergic neurons. Rats were given test agents or vehicle, intraperitoneally, before recording motor activity for 90 min at PD 25 in a novel environment. d-Methylphenidate stimulated motor activity in sham controls and antagonized hyperactivity in lesioned rats. Selective DA transport inhibitors GBR-12909 and amfonelic acid greatly stimulated motor activity in sham control subjects, too, but did not antagonize hyperactivity in lesioned rats. In contrast, all selective 5-HT and NE transporter antagonists tested greatly reduced motor hyperactivity in 6-OHDA lesioned rats but did not alter motor activity in sham controls. The findings indicate that behavioral effects of stimulants in young rats with neonatal 6-OHDA lesions may be mediated by release of NE or 5-HT and support interest in using drugs that increase activity of norepinephrine or serotonin to treat ADHD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023542     DOI: 10.1124/jpet.301.3.1097

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  27 in total

1.  Modeling of chronic selective inhibition of noradrenaline synthesis in the brain of neonatal rats.

Authors:  Y O Zubova; N S Bondarenko; A Ja Sapronova; M V Ugrumov
Journal:  Dokl Biochem Biophys       Date:  2015-05-05       Impact factor: 0.788

Review 2.  Animal models to guide clinical drug development in ADHD: lost in translation?

Authors:  Jeffery R Wickens; Brian I Hyland; Gail Tripp
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  A high density linkage disequilibrium mapping in 14 noradrenergic genes: evidence of association between SLC6A2, ADRA1B and ADHD.

Authors:  Ziarih Hawi; Natasha Matthews; Edwina Barry; Aiveen Kirley; Joseph Wagner; Robyn H Wallace; Helen S Heussler; Alasdair Vance; Michael Gill; Mark A Bellgrove
Journal:  Psychopharmacology (Berl)       Date:  2012-09-29       Impact factor: 4.530

4.  The role of dopaminergic transmission through D1-like and D2-like receptors in amphetamine-induced rat ultrasonic vocalizations.

Authors:  Jennifer M Wright; May R S Dobosiewicz; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2012-09-28       Impact factor: 4.530

5.  Organic cation transporter 3 contributes to norepinephrine uptake into perivascular adipose tissue.

Authors:  Nadia Ayala-Lopez; William F Jackson; Robert Burnett; James N Wilson; Janice M Thompson; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-02       Impact factor: 4.733

6.  Sex-dependent changes in ADHD-like behaviors in juvenile rats following cortical dopamine depletion.

Authors:  Nadja Freund; Heather T MacGillivilray; Britta S Thompson; Jodi L Lukkes; Jessica J Stanis; Heather C Brenhouse; Susan L Andersen
Journal:  Behav Brain Res       Date:  2014-05-23       Impact factor: 3.332

7.  The effects of the 5-HT(2C) receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists.

Authors:  Paul J Fletcher; Judy Sinyard; Guy A Higgins
Journal:  Psychopharmacology (Berl)       Date:  2006-07-11       Impact factor: 4.530

Review 8.  Pharmacological models of ADHD.

Authors:  R M Kostrzewa; J P Kostrzewa; R A Kostrzewa; P Nowak; R Brus
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

9.  The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.

Authors:  Gor Sarkisyan; Amanda J Roberts; Peter B Hedlund
Journal:  Behav Brain Res       Date:  2010-01-25       Impact factor: 3.332

10.  Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.

Authors:  Feng Liu; Haruka Minami; Raul R Silva
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.